StockNews.com Upgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Buy

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP stock opened at $2.47 on Wednesday. Oramed Pharmaceuticals has a 52 week low of $1.67 and a 52 week high of $3.67. The firm’s 50-day simple moving average is $2.43 and its two-hundred day simple moving average is $2.48. The firm has a market cap of $100.35 million, a price-to-earnings ratio of 9.50 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.01 by $0.21. Analysts forecast that Oramed Pharmaceuticals will post 0.24 earnings per share for the current year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ORMP. XTX Topco Ltd bought a new position in Oramed Pharmaceuticals during the 2nd quarter worth approximately $40,000. Assenagon Asset Management S.A. bought a new position in Oramed Pharmaceuticals in the 1st quarter worth $54,000. Virtu Financial LLC bought a new stake in Oramed Pharmaceuticals during the 1st quarter valued at approximately $68,000. Dimensional Fund Advisors LP grew its stake in Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares during the period. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.